title: Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis.
abstract: When cystic fibrosis (CF) is suspected Nasal Potential Difference (NPD) measurements are proposed to support controversial diagnosis: we investigated appropriate outcomes at the CF Centre of Verona.
  
  
  
  NPD were measured in 196 subjects: 50 non-CF, 65 classical CF (the reference group) and 81 with uncertain CF (case group). Discriminating power was determined by comparison between several outcomes from the CF reference group versus non-CF: basal, amiloride, 0Cl, isoproterenol, ATP, Delta-amiloride, Delta-0Cl, Delta-isoproterenol, Delta-ATP, Delta-isoproterenol+Delta-0Cl, Wilschanski Index (WI) and Sermet score (SS). The most appropriate cut-off values for variables with the best discriminating power were then applied to the case group. Descriptive statistics, logistic regression models and ROC curve analysis were applied.
  
  
  
  WI and SS were the most powerful in discriminating CF from non-CF subjects. In the reference group sensitivity of the 0.82 WI cut-off was 98%, specificity 96%; both sensitivity and specificity of the -0.44 SS cut-off value were 100%. For the case group, WI and SS were, respectively, consistent with CF diagnosis in 94% and 92% of the cases.
  
  
  
  Formulae have the highest discriminating power and can support the diagnosis in uncertain cases; they should be utilized for standardized interpretation of NPD for diagnosis and possibly for clinical research.
authors.affiliation: Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
authors.forename: Gloria
authors.initials: G
authors.lastname: Tridello
authors.affiliation: Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Menin
authors.affiliation: Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
authors.forename: Emily
authors.initials: E
authors.lastname: Pintani
authors.affiliation: Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Italy; Department of Pathology and Diagnostics Medicine, Cystic Fibrosis Translational Research Laboratory "Daniele Lissandrini", University of Verona, 37134 Verona, Italy.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Bergamini
authors.affiliation: Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Italy.
authors.forename: Baroukh Maurice
authors.initials: BM
authors.lastname: Assael
authors.affiliation: Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria Integrata Verona, Italy. Electronic address: paola.melotti@ospedaleuniverona.it.
authors.forename: Paola
authors.initials: P
authors.lastname: Melotti
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000584:Amiloride / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000175:diagnosis*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D003937:Diagnosis, Differential; D016002:Discriminant Analysis; D004553:Electric Conductivity; D062686:Epithelial Sodium Channel Blockers / Q000494:pharmacology; D005260:Female; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology*; D008297:Male; D008564:Membrane Potentials; D009093:Mucus / Q000378:metabolism*; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism; D012372:ROC Curve; D012680:Sensitivity and Specificity; D013542:Sweat / Q000737:chemistry / Q000378:metabolism
chemical_list: D000318:Adrenergic beta-Agonists; D062686:Epithelial Sodium Channel Blockers; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D000584:Amiloride; D007545:Isoproterenol
keywords: CFTR genetic test; CFTR related disorders; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Diagnosis; Nasal potential difference measurements; Sweat test